ArticleMicrobial cell factories2015
Metabolic engineering of Escherichia coli for enhanced arginine biosynthesis.
Article in Microbial cell factories, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 76 citations in OpenAlex.
- Construction of an engineered Escherichia coli strain with enhanced intestinal colonization and anti-inflammatory efficacy in colitis.Cellular & molecular immunology · 2026Article
- Engineering of a LysG-derived arginine-specific biosensor for high-throughput screening of arginine overproducers in Corynebacterium glutamicum.Biotechnology for biofuels and bioproducts · 2026Article
- Long-term homeostasis in microbial consortia via auxotrophic cross-feeding.Nature communications · 2025Article
- Reconstitution of Methionine Cycle With ATP Regeneration for Whole-Cell Catalysis of Creatine Production in Engineered Escherichia coli.Microbial biotechnology · 2025Article
- Rationally Engineering pH Adaptation of Acid-Induced Arginine Decarboxylase from Escherichia coli to Alkaline Environments to Efficiently Biosynthesize Putrescine.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Characterizing arginine, ornithine, and putrescine pathways in enteric pathobionts.MicrobiologyOpen · 2024Article
- Article
- Biosynthesis of novel non-proteinogenic amino acids β-hydroxyenduracididine and β-methylphenylalanine inFrontiers in bioengineering and biotechnology · 2024Article
- A novel strategy for L-arginine production in engineered Escherichia coli.Microbial cell factories · 2023Article
- Recent advances in bacterial therapeutics based on sense and response.Acta pharmaceutica Sinica. B · 2023Review
- TheMicroorganisms · 2022Article
- High-level production of the agmatine in engineered Corynebacterium crenatum with the inhibition-releasing arginine decarboxylase.Microbial cell factories · 2022Article
- Improvement of putrescine production through the arginine decarboxylase pathway in Escherichia coli K-12.AMB Express · 2021Article
- Production of l-glutamate family amino acids inSynthetic and systems biotechnology · 2021Review
- Engineered Interspecies Amino Acid Cross-Feeding Increases Population Evenness in a Synthetic Bacterial Consortium.mSystems · 2019Article
- Simultaneous Quantification of L-arginine and Monosaccharides during Fermentation: An Advanced Chromatography Approach.Molecules (Basel, Switzerland) · 2019Article
- Metabolic engineering ofEngineering in life sciences · 2019Article
- In silico model-guided identification of transcriptional regulator targets for efficient strain design.Microbial cell factories · 2018Article
- Engineering Escherichia coli to grow constitutively on D-xylose using the carbon-efficient Weimberg pathway.Microbiology (Reading, England) · 2018Article
- A versatile one-step CRISPR-Cas9 based approach to plasmid-curing.Microbial cell factories · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundArginine is a high-value product, especially for the pharmaceutical industry. Growing demand for environmental-friendly and traceable products have stressed the need for microbial production of this amino acid. Therefore, the aim of this study was to improve arginine production in Escherichia coli by metabolic engineering and to establish a fermentation process in 1-L bioreactor scale to evaluate the different mutants.
resultsFirstly, argR (encoding an arginine responsive repressor protein), speC, speF (encoding ornithine decarboxylases) and adiA (encoding an arginine decarboxylase) were knocked out and the feedback-resistant argA214 or argA215 were introduced into the strain. Three glutamate independent mutants were assessed in bioreactors. Unlike the parent strain, which did not excrete any arginine during glucose fermentation, the constructs produced between 1.94 and 3.03 g/L arginine. Next, wild type argA was deleted and the gene copy number of argA214 was raised, resulting in a slight increase in arginine production (4.11 g/L) but causing most of the carbon flow to be redirected toward acetate. The V216A mutation in argP (transcriptional regulator of argO, which encodes for an arginine exporter) was identified as a potential candidate for improved arginine production. The combination of multicopy of argP216 or argO and argA214 led to nearly 2-fold and 3-fold increase in arginine production, respectively, and a reduction of acetate formation.
conclusionsIn this study, E. coli was successfully engineered for enhanced arginine production. The ∆adiA, ∆speC, ∆speF, ∆argR, ∆argA mutant with high gene copy number of argA214 and argO produced 11.64 g/L of arginine in batch fermentation, thereby demonstrating the potential of E. coli as an industrial producer of arginine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.